Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcoma

Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcoma

PurposeUterine leiomyosarcoma is a rare and aggressive tumor known for its drug resistance and metastatic potential. The standard first-line treatment typically involves anthracycline-based chemotherapy or a combination of gemcitabine and docetaxel; however, there is currently no established second-...

Full description

Bibliographic Details
Main Authors:	Szu-Yun Niu, Lou Sun, Shih-Tien Hsu, Sheau-Feng Hwang, Chih-Ku Liu, Yu-Hsiang Shih, Ting-Fang Lu, Yen-Fu Chen, Li-Ching Lai, Pei-Lun Chang, Chien-Hsing Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Oncology
Subjects:	uterine leiomyosarcoma second-line treatment doxorubicin plus ifosfamide gemcitabine plus docetaxel adjuvant chemotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1282596/full

Similar Items

Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas
by: Angela Buonadonna, et al.
Published: (2023-10-01)

Ifosfamide-induced extrapyramidal neurotoxicity with COVID-19
by: Chitrakshi Nagpal, et al.
Published: (2023-01-01)

Case report: Malignant transformation of ovarian endometrioma during long term use of dienogest in a young lady
by: Yi-Ting Chang, et al.
Published: (2024-01-01)

Neuropsychiatric Toxicity of Ifosfamide in Patients Admitted for Chemotherapy
by: Mohammadali Mashhadi, et al.
Published: (2010-01-01)

Neuropsychiatric Toxicity of Ifosfamide in Patients Admitted for Chemotherapy
by: Mohammadali Mashhadi, et al.
Published: (2010-03-01)

Inflammatory Surrogate Parameters for Predicting Ifosfamide-Induced Neurotoxicity in Sarcoma Patients
by: Moritz Schmidt, et al.
Published: (2022-09-01)

Investigation of Ifosfamide Toxicity Induces Common Upstream Regulator in Liver and Kidney
by: Hyoung-Yun Han, et al.
Published: (2021-11-01)

Induced resistance to ifosfamide in osteosarcoma cells suggests a more aggressive tumor profile
by: Maria Tereza de Oliveira Rodrigues, et al.
Published: (2022-12-01)

Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series
by: Hisaki Aiba, et al.
Published: (2023-04-01)

Protective Effect of Daidzein on Ifosfamide-Induced Neurotoxicity Via Improving Some Selected Oxidative Stress Parameters in Male Rats
by: Hiba Zaki Hammodi, et al.
Published: (2023-11-01)

Misdiagnosis and mistreatment of uterine myxoid leiomyosarcoma: A case report and literature review
by: Ruiping Li, et al.
Published: (2023-07-01)

Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors—A Sarcoma Reference Center Experience
by: Paweł Sobczuk, et al.
Published: (2020-09-01)

A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature
by: Gabriel Chain, et al.
Published: (2022-02-01)

Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy
by: Yen-Fu Chen, et al.
Published: (2024-01-01)

Rare Delayed Ifosfamide Encephalopathy: A Case Report of Chemotherapeutic Neurotoxicity
by: Ambika Menon, et al.
Published: (2024-02-01)

Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
by: Evgeny M. Kirilin, et al.
Published: (2022-04-01)

Attenuation of Ifosfamide Adverse Effect on Leydig, Sertoli and Spermatogonia Cells of Ram Testis by Liposome Technique in vitro
by: Mohanad A. Al-Bayati, et al.
Published: (2019-02-01)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
by: Takafumi Mie, et al.
Published: (2023-01-01)

Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration
by: Abigail Ferreira, et al.
Published: (2021-12-01)

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
by: Alberto Servetto, et al.
Published: (2021-09-01)

Laryngeal Leiomyosarcoma
by: Burak ERTAŞ, et al.
Published: (2018-01-01)

Association of chondroadherin with leiomyosarcoma
by: Sefik Gokce, et al.
Published: (2023-04-01)

A rare case of intracardiac metastasis of uterine leiomyosarcoma
by: Khadije Mohammadi, et al.
Published: (2022-10-01)

Uterine leiomyosarcoma in a dog: a case report
by: G. Serin, et al.
Published: (2010-08-01)

Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study)
by: Ou Yamaguchi, et al.
Published: (2024-01-01)

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
by: Yongchang Zhang, et al.
Published: (2022-09-01)

Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma
by: Minggui Pan, et al.
Published: (2021-04-01)

The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma
by: Jingwen Zhang, et al.
Published: (2024-02-01)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
by: Qi Quan, et al.
Published: (2020-12-01)

Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
by: Daniela Dias, et al.
Published: (2023-05-01)

Renal toxicity of ifosfamide in children with cancer: an exploratory study integrating aldehyde dehydrogenase enzymatic activity data and a wide-array urinary metabolomics approach
by: Olivia Febvey-Combes, et al.
Published: (2024-03-01)

Posterior mediastinal epithelioid leiomyosarcoma: Case report and literature review
by: Cosmin Iacoban, DO, et al.
Published: (2022-03-01)

Development of a new vesicular formulation for delivery of Ifosfamide: Evidence from in vitro, in vivo, and in silico experiments
by: Mohammad Reza Hajinezhad, et al.
Published: (2023-09-01)

Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis
by: Thomas J. Carter, et al.
Published: (2020-11-01)

A case of metastatic endobronchial tumor from uterine leiomyosarcoma
by: Manabu Ono, et al.
Published: (2022-01-01)

(Nec) Plus Ultra: as epopeias antes e após as grandes navegações
by: Cleber Vinicius do Amaral Felipe
Published: (2020-04-01)

An unusual case of hepatic metastasis from uterine leiomyosarcomas
by: Mengling Cui, et al.
Published: (2023-09-01)

Rate of Leiomyosarcomas during Surgery for Uterine Fibroids: 8-Year Experience of a Single Center
by: Dimitrios Zouzoulas, et al.
Published: (2023-12-01)

Case report: A case of oviductal and uterine leiomyosarcoma in an 11-year-old dog
by: Jillian Kazmierczak, et al.
Published: (2023-12-01)

When Vessels and Sarcomas Combine: A Review of the Inferior Vena Cava Leiomyosarcoma
by: João Martins Gama, et al.
Published: (2024-01-01)